Breast density is a measure of the composition of the breast tissue. Breasts with low density have a high proportion of fatty (F) tissue, whereas breasts with high density have a high proportion of epithelial and connective tissue. Mammography has a lower sensitivity in women with mixed/dense (M/D) breasts than in women with F breasts ([Mandelson *et al*, 2000](#bib9){ref-type="other"}, [Ciatto *et al*, 2004](#bib6){ref-type="other"}; [Chiarelli *et al*, 2006](#bib5){ref-type="other"}), and women with M/D breasts have a higher incidence of breast cancer (BC) than women with F breasts ([McCormack and dos Santos Silva, 2006](#bib10){ref-type="other"}; [Boyd *et al*, 2007](#bib3){ref-type="other"}). We therefore examined whether breast density affects the outcome of mammography screening using data from the organised mammography screening programme in Copenhagen, Denmark, earlier shown to reduce BC mortality in targeted women by 25% and in participating women by 37% ([Olsen *et al*, 2005](#bib12){ref-type="other"}).

We tested the following hypotheses: compared with women with F breasts, (1) the sensitivity of mammography is lower in women with M/D breasts, and (2) women with M/D breasts have a higher BC incidence. Our results were well in accordance with those of earlier studies. We further tested whether: (3) because of the lower sensitivity the case fatality rate of BC patients with M/D breasts will be higher than that of patients with F breasts, and (4) screened women with M/D breasts will experience a higher BC mortality than screened women with F breasts. This study is the first to report on the effect of breast density on BC mortality in screened women.

Materials and methods
=====================

This study was based entirely on data available in administrative registers; it was approved by the Danish Data Inspection Agency. The Copenhagen mammography screening programme started on 1 April 1991 ([Vejborg *et al*, 2002](#bib16){ref-type="other"}). The programme targets women aged 50--69 years at the start of each biennial invitation round. All women are personally invited to participate. About 40 000 women are invited in each invitation round. From the very beginning, all screening has taken place at one clinic dedicated to screening and placed at one of the Copenhagen hospitals. The clinic has three Instrumentarium mammography equipments (Instrumentanium Corp., Imaging Division, Tuusula, Finland) changed over time from Alpha III to Alpha RT. Over time, only two radiologists have been in charge of the screening programme, the first one in 1991--96, and the second (IV) still heads the programme. Attending women are asked to fill in a short questionnaire on hormone therapy (HRT) use, earlier breast surgery, family history of BC, and eventual suspicion of a breast lump. These data were, however, not entered in the database. All screens are taken by the radiographers, and the attending women do not see the radiologist. All mammograms are centrally evaluated independently by two radiologists, to whom only the age of the women and the questionnaire answers are available. At subsequent screens, mammograms are compared with those taken in the earlier screening rounds.

At the first screen, all women had two views taken of each breast, a craniocaudal and an oblique view. During the study period, breast density was dichotomised into F breasts, equivalent to BI-RADS ([Breast Imaging Reporting and Data System (BI-RADS) Atlas, 2008)](#bib4){ref-type="other"} density code 1 and part of code 2, and M/D breasts. Women with a negative screening test and F breasts were scheduled to have only an oblique view made at the next screen, whereas women with a negative screening test and M/D breasts were scheduled for two views. The decision on one or two views was based entirely on density. Density was also evaluated at subsequent screens. The dichotomised density codes were entered in the database for the mammography screening programme and used in this study.

Data from the first five biennial invitation rounds were retrieved from the administrative file of the mammography screening programme. Data on date of death or emigration came from the Central Population Register, on cause of death from the Cause of Death Register, and on incident BC cases from the Cancer Register, the Danish Breast Cancer Cooperative Group, and from the screening data. Incident cases of BC included both invasive BC and DCIS. Data on oestrogen receptor status were collected by the Danish Breast Cancer Cooperative Group from local pathology laboratories, in which primarily immunohistochemical tests were used. A tumour was classified as positive if 10% or more of the cells stained positive. Progesterone receptor status was available only for 37% of invasive cancers, so these data were not included in the analysis. The data files were linked using the unique personal identification numbers issued to all persons with a permanent address in Denmark.

Analysis
--------

For the analysis of BC incidence, BC mortality and case fatality, women diagnosed before entering the screening programme were excluded, as were women diagnosed with BC at first screen, because they never received a breast density code. For BC incidence, women were followed up from their first negative screen -- taking place between 1 April 1991 and 1 April 2001 -- until BC diagnosis, death, emigration, or end of follow-up, which was on 1 April 2001. All incident BC cases during the follow-up period were included in the analysis irrespective of whether the mode of detection was at screening, as interval cancer up until 2 years after last screen, or diagnosed more than 2 years after the women left the screening programme. For case fatality, women were followed up from date of diagnosis with BC until date of death, emigration, or end of follow-up on 1 April 2001. For BC mortality, women were followed up from their first negative screen until date of death, emigration, or end of follow-up.

For the sensitivity analysis, screen-detected and interval cancers were defined as above, and the sensitivity of mammography screening in M/D breasts compared with that of F breasts was calculated as the age-adjusted ratio of the odds for interval cancers *versus* screen-detected cancers in the two groups ([Mandelson *et al*, 2000](#bib9){ref-type="other"}; [Chiarelli *et al*, 2006](#bib5){ref-type="other"}).

Person years, incident BC cases, and BC deaths were divided into groups corresponding to the breast density status. At each screen, the woman entered the status recorded for her at that screen, and she remained in this status until end of follow-up unless her status changed at a later screen; if so, she changed status. If a BC was diagnosed at screening, the woman remained for the case fatality and mortality analysis in the status group recorded at her earlier screen until the end of follow-up. BC incidence and mortality were compared between the two breast density groups, and age-adjusted rate ratios were calculated using Poisson regression. The low breast density group was used as the baseline. Poisson regression was used also for comparison of the age-adjusted case fatality rates between BC patients with M/D and F breasts, respectively, in which death from any cause was counted as an event.

Results
=======

During the first 10 years of the Copenhagen mammography screening programme, a total of 134 640 screens were made and 989 BC cases detected, [Table 1](#tbl1){ref-type="table"}. In total, 46% of the negative screens were taken of F breasts. This proportion declined over time from 53% in the first round in 1991--1993 to 36% in the fifth round in 1999--2001. This decline was most pronounced in women aged 50--54 years at the time of screening, in which the percentage changed from 42% in 1991--1993 to 21% in 1999--2001, whereas only a small change was seen over time in the oldest women. The 134 650 screens were taken in a total of 48 052 women, of whom 90% experienced no change in density status during their participation in the programme, 8% experienced one, and the remaining 2% of women experienced two to four shifts.

In the F breast group, in total 158 950 person years were accumulated for the BC mortality analysis, [Table 2](#tbl2){ref-type="table"}. The 315 incident BCs, comprised 159 screen-detected, 65 interval, and 91 cancers diagnosed after leaving the screening programme. The interval cancers constituted 29% of the total of screen-detected and interval cancers. In total, 37 BC deaths were observed in the F breast group, resulting in a BC mortality rate of 23 per 100 000 person years. In the M/D breast group, in total 157 594 person years were accumulated. The 694 incident BCs comprised 312 screen-detected, 214 interval, and 168 cancers diagnosed after leaving the screening programme. The interval cancers constituted 41% of the total of screen-detected and interval cancers. In total, 53 BC deaths were observed in the M/D breast group, a BC mortality rate of 34 per 100 000 person years. The age-adjusted odds ratio for an interval cancer *vs* a screen-detected cancer was 1.62 (95% confidence interval, CI, 1.14--2.30) in women with M/D breasts compared with women with F breasts.

The BC incidence rate ratio, as estimated in the Poisson regression using the F breast group as baseline, was 2.45 (95% CI 2.14--2.81), being 2.39 (95% CI 2.08--2.75) for invasive cancer and 3.40 (95% CI 2.02--5.73) for DCIS, [Table 3](#tbl3){ref-type="table"}. For invasive cancer, the rate ratios were 2.53 (95% CI 2.13--3.02) for oestrogen receptor-positive cancers and 1.53 (95% CI 1.11--2.12) for oestrogen receptor-negative cancers. The case fatality rate of BCs in M/D breasts was 0.60 (95% CI 0.43--0.84) of that of BCs in F breasts. The age-adjusted BC mortality rate ratio was 1.78 (95% CI 1.17--2.72).

Discussion
==========

On the basis of the Copenhagen mammography screening programme, we tested four hypotheses on differences between M/D and F breasts. The first was confirmed, as the sensitivity of mammography was lower with M/D than with F breasts indicated by the risk of an interval *vs* a screen-detected cancer being 1.6. The second was also confirmed, as BC incidence was 2.5 times higher in women with M/D than in those with F breasts. The third hypothesis was, however, not confirmed, as the relative risk (RR) for the case fatality rate of cancers in M/D compared with F breasts was 0.6. The fourth hypothesis concerning BC mortality was confirmed, but the better case fatality rate partly compensated for the higher incidence in women with M/D breasts, resulting in BC mortality for these women being only 1.8 times that of women with F breasts.

In this study, women were screened in the age group 50--69 years, and on average, 54% of the women had M/D breasts deemed from the recommendation of two-view mammography at next screen. As our cutoff point for M/D breasts included BI-RADS density codes 4, 3, and part of code 2, this was well in accordance with an earlier study, in which 13% of screens had BI-RADS density code 1; 53% had code 2; and 34% had codes 3 or 4 ([Kerlikowske *et al*, 2007](#bib7){ref-type="other"}). Our data showed a drift over time towards the M/D category, which is probably partly explained by an increasing use of HRT during the study period ([Olesen *et al*, 1999](#bib11){ref-type="other"}; [Løkkegaard *et al*, 2007](#bib8){ref-type="other"}).

As the data were collected from comprehensive, administrative registers, the study was not affected by recall or reporting bias. However, it only covered women attending mammography screening, which in Copenhagen included about 80% of targeted women ([von Euler-Chelpin *et al*, 2006](#bib17){ref-type="other"}). There is, nevertheless, no reason to expect that attending women constituted a biased sample, as women do not *a priori* know their breast density.

The odds ratio, of interval *versus* screen-detected cancer, of 1.62 (95% CI 1.14--2.30) between the two groups, was in line with earlier studies indicating a lower sensitivity of mammography in M/D than in F breasts ([Mandelson *et al*, 2000](#bib9){ref-type="other"}; [Chiarelli *et al*, 2006](#bib5){ref-type="other"}).

The rate ratio of incident BC was 2.45 (95% CI 2.14--2.81) in women with M/D compared with those with F breasts. Taking into account the difference in the cutoff points used for the M/D breast category across studies, our result was well in line with earlier findings ([McCormack and dos Santos Silva, 2006](#bib10){ref-type="other"}; [Boyd *et al*, 2007](#bib3){ref-type="other"}). One could argue that the increased incidence in women with M/D breasts in our study was an artefact because of the more intensive screening using two-view mammography. If this was the case, a greater sensitivity in this group would be expected, which was not so.

Despite the lower sensitivity of mammography screening in M/D than in F breasts, we found that patients with M/D breasts had a better survival, with a case fatality rate ratio of 0.60 (95% CI 0.43--0.84). Using an alternative calculation with competing risks only slightly changed the case fatality rate to 0.56 (95% CI 0.36--0.87). Including only deaths from BC gave a case fatality rate ratio of 0.53 (95%CI 0.34--0.82). An earlier study indicated a slightly worse BC-specific survival for BI-RADS category 2 cancers than for category 1, 3, and 4 cancers ([Porter *et al*, 2007](#bib14){ref-type="other"}).

Although M/D breasts were associated with 2.5 times the risk of BC compared with F breasts, they ended up with a BC mortality of only 1.8 times higher. Data on BC mortality by breast density have not been reported earlier, although hormone use is known to delay breast tissue transition from M/D to F ([Persson *et al*, 1997](#bib13){ref-type="other"}). Current hormone users at recruitment to the Million Women Study had, during a follow-up period of about 4 years, a relative risk of BC incidence of 1.66 (95% CI 1.60--1.72) compared with never users, whereas their relative BC mortality risk was only 1.22 (95%CI 1.05--1.41) ([Beral *et al*, 2003](#bib2){ref-type="other"}). A similar pattern was seen in the Danish Nurses\' Health Study, in which the current HRT use was associated with a rate ratio of 2.42 (95% CI 1.81--3.26) for BC incidence and of 1.97 (95% CI 1.14--3.42) for BC mortality ([Stahlberg *et al*, 2005](#bib15){ref-type="other"}).

The excess BC risk in women with M/D breasts came mainly from oestrogen receptor-positive tumours, RR 2.53 (95% CI 2.13--3.02), although these women also had an excess risk of oestrogen receptor-negative tumours, RR 1.53 (95% CI 1.11--2.12). This accorded with data from an earlier study ([Ziv *et al*, 2004](#bib18){ref-type="other"}). Oestrogen receptor-positive BC patients have a better 5-year survival than oestrogen receptor-negative patients ([Bentzon *et al*, 2008](#bib1){ref-type="other"}), and the oestrogen receptor status data in our study were therefore in line with our finding on case fatality.

Participants in the Copenhagen mammography screening programme on average experienced a 37% lower BC mortality than expected in the absence of screening ([Olsen *et al*, 2005](#bib12){ref-type="other"}). A special effort using two-view mammography was made to diagnose BC in women with M/D breasts, but was, however, not sufficient to bring the BC mortality of screening participants with M/D breasts in line with that of participants with F breasts. This is not surprising, as the sensitivity despite the special effort was lower in women with M/D breasts than in women with F breasts.

This study has shown that, although BC is more frequent in women with M/D than in those with F breast, the BCs of women with M/D breasts seem on average to be less severe.

This study was funded by the Danish Cancer Society.

###### 

Participants in first--fifth invitation round of the mammography screening programme in Copenhagen, Denmark, 1991--2001. Women aged 50--69 years at the start of each invitation round

                                           **Outcome of screening**                                               
  --------------------------------------- -------------------------- ----- ----- -------- -------- ---- --------- ----
  First, 1 April 1991--25 April 1993                 316              44    360   15 805   14 197   33   30 395    53
  Second, 26 April 1993--31 May 1995^b^              162              21    183   14 615   13 779   28   28 605    51
  Third, 1 June 1995--24 March 1997                  136              18    154   11 666   13 317   13   25 150    47
  Fourth, 25 March 1997--19 April 1999               129              18    147   10 670   14 602   9    25 428    42
  Fifth, 20 April 1999--31 March 2001                123              22    145    8985    15 928   4    25 062    36
  Total                                              866              123   989   61 741   71 823   87   134 640   46

Abbreviation: DCIS=ductal carcinoma *in situ.*

Coding errors.

The invitation round targeted women aged 50--71 years.

###### 

Number of person years at risk, screen-detected breast cancers, interval breast cancers, other breast cancers, and breast cancer deaths by density code and age at diagnosis

            **Fatty breasts**   **Mixed/dense breasts**                                                                  
  -------- ------------------- ------------------------- ------- ---- ----- ---- --------- -------- -------- ----- ----- ----
  50--54         14 811                    5                4     0     9    0    31 435      33       39      8    80    3
  55--59         30 621                   24               11     8    43    3    40 464      88       56     22    166   7
  60--64         33 710                   55               15     13   83    6    30 541      80       52     36    168   14
  65--69         37 236                   53               18     12   83    12   27 242      86       38     18    142   12
  70--74         32 072                   22               17     27   66    11   21 347      25       29     55    109   9
  75--79         10 500                    0                0     31   31    5     6565       0        0      29    29    8
  Total          158 950                159^e^            65^e^   91   315   37   157 594   312^e^   214^e^   168   694   53

Abbreviation: CI=confidence intervals; DCIS=ductal carcinoma *in situ*.

Invasive breast cancer and DCIS.

Screen-detected breast cancer.

Breast cancer diagnosed \<2 years after the last screening date.

Breast cancer diagnosed ⩾2 years after the last screening date.

Age-adjusted odds ratio of interval cancer *versus* screen-detected cancer in women with two-view compared with women with one-view mammography 1.62 (95% CI 1.14--2.30).

###### 

Breast cancer incidence by stage and oestrogen-receptor status, breast cancer case fatality and breast cancer mortality by density

                                        **Fatty breasts**   **Mixed/dense**                         
  ------------------------------------ ------------------- ----------------- ----- --------- ------ ------------
  *Breast cancer incidence*                                                                         
   Total                                       315              158 017       694   155 110   2.45   2.14--2.81
   Invasive only                               296              158 017       634   155 110   2.39   2.08--2.75
   DCIS only                                   19               158 017       60    155 110   3.40   2.02--5.73
                                                                                                          
  *Invasive breast cancer incidence*                                                                
   Oestrogen receptor positive                 188              158 017       421   155 110   2.53   2.13--3.02
   Oestrogen receptor negative                 64               158 017       94    155 110   1.53   1.11--2.12
   Oestrogen receptor unknown                  44               158 017       119   155 110   3.05   2.15--4.33
  Breast cancer case fatality                 60^b^              1988         86     4725     0.60   0.43--0.84
  Breast cancer mortality                     37^c^             158 950       53    157 594   1.78   1.17--2.72

Abbreviation: DCIS=ductal carcinoma *in situ.*

Age-adjusted, Poisson regression.

All deaths.

Breast cancer deaths.
